Premium
Patient preferences for treatment of advanced melanoma: impact of comorbidities
Author(s) -
Weilandt Juliane,
Diehl Katharina,
Schaarschmidt MartheLisa,
Kiecker Felix,
Sasama Bianca,
Pronk Melanie,
Ohletz Jan,
Könnecke Andreas,
Müller Verena,
Utikal Jochen,
Hillen Uwe,
Harth Wolfgang,
Peitsch Wiebke K.
Publication year - 2021
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/ddg.14293
Subject(s) - medicine , discontinuation , comorbidity , adverse effect , depression (economics) , multivariate analysis , diabetes mellitus , oncology , economics , macroeconomics , endocrinology
Summary Background and objectives Choice of treatment for advanced melanoma is crucially influenced by comorbidities and patient preferences. Our study aimed to investigate the impact of comorbidities on preferences. Patients and methods 150 patients with melanoma stage IIC–IV completed a discrete choice experiment to determine preferences for outcome (overall response rate [ORR], 2‐year survival, progression‐free survival [PFS], time to response [TTR], kind of adverse events [AE], AE‐related treatment discontinuation) and process attributes (frequency and route of administration [RoA], frequency of consultations) of systemic melanoma treatments. The impact of comorbidities was assessed by analysis of variance and multivariate regression. Results Participants with hypertension and other cardiovascular diseases attached significantly greater importance to TTR and RoA than others. Respondents with arthropathy cared more about TTR (β = 0.179, P = 0.047) and RoA, but less about ORR (β = –0.209, P = 0.021). Individuals with diabetes considered AE (β = 0.185, P = 0.039) and frequency of consultations more essential, but ORR less relevant. Those with other malignancies were particularly worried about treatment discontinuation (β = 0.219, P = 0.008), but less about ORR (β = –0.202, P = 0.015). Participants with depression focused more on PFS (β = 0.201, P = 0.025) and less on TTR (β = –0.201, P = 0.023) and RoA (β = –0.167, P = 0.050). Conclusions Treatment preferences of melanoma patients vary significantly dependent on comorbidities.